Lancaster Disease (must read, learn in 5 minutes)

Treacher Collins syndrome (TCS), also known as Mandibulofacial Dysostosis (OMIM #154500) or historically as Franceschetti-Zwahlen-Klein syndrome, is a rare autosomal dominant craniofacial disorder characterized by bilateral symmetric anomalies of the first and second pharyngeal arches. It primarily affects the development of bones and soft tissues of the face, particularly the mandible, zygomatic complex, external ears, and eyes.

Historical Background

First described in 1900 by British ophthalmologist Edward Treacher Collins—who reported ocular and facial anomalies in multiple family members—the condition was formally articulated in his seminal 1933 paper presented to the Ophthalmological Section of the Royal Society of Medicine (then known as the Opthamology Society of Great Britain and Ireland). His detailed clinical observations laid the foundation for recognizing TCS as a distinct entity. Later, Franceschetti, Zwahlen, and Klein expanded the phenotypic description in 1946, emphasizing the mandibular and auricular defects.

Genetics & Molecular Pathogenesis

TCS is primarily caused by mutations disrupting ribosome biogenesis (a condition termed ribosomopathy), leading to impaired neural crest cell proliferation, migration, and increased apoptosis during embryogenesis (1–2 weeks post-fertilization), critical for craniofacial development.

• TCOF1 (Treacle): Accounts for 80–93% of cases. Located on chromosome 5q35. Encodes a nucleolar phosphoprotein essential for ribosomal RNA (rRNA) processing.
• POLR1C and POLR1D: Responsible for 2–8% and ~5% of cases, respectively. Encode subunits of RNA polymerases I and III. POLR1C exhibits biallelic inheritance (autosomal recessive in some families), while POLR1D can manifest as dominant or recessive.

Approximately 40–60% of cases arise from de novo pathogenic variants, with no family history. Penetrance is complete but expressivity is highly variable—even among affected relatives—due to modifier genes and stochastic developmental factors.

Sources:
– Koomoa et al., Genetics in Medicine (2023)
– Trainor & Bond, Nature Reviews Disease Primers (2021)
– Online Mendelian Inheritance in Man (OMIM #154500); ClinVar database

Epidemiology

• Incidence: ~1 in 50,000 live births (range 1:10,000–1:100,000), consistent across global populations (European, Asian, African descent)
• Sex ratio: Equal male-to-female distribution (M:F ≈ 1:1)
• No ethnic predilection reported in large cohort studies (e.g., EUROPAC consortium)

Clinical Features & Phenotypic Spectrum

TCS exhibits a wide clinical spectrum, from mild (isolated ear anomalies) to severe (life-threatening airway compromise in neonates). Key features include:

Craniofacial Manifestations

• Mandible: Hypoplastic mandible (micrognathia/retrognathia), leading to glossoptosis, upper airway obstruction, and respiratory distress in neonates.
  • Management insight: Positioning (lateral/side-lying sleep), nasopharyngeal airway, or tracheostomy may be required acutely. Cleft palate occurs in ~30–40% of cases.
• Midface: Hypoplastic zygomatic bones and malar flattening give the pseudo-proptotic appearance of a “large nose.” Maxillary hypoplasia contributes to malocclusion and dental crowding.
• Eyes:
  • Classic downslanting palpebral fissures
  • Lower lid colobomas (notched defects) in ~65% of cases
  • Absent eyelashes over colobomas
  • Orbital dysmorphology may cause exposure keratopathy, strabismus, or amblyopia. Visual acuity is usually preserved unless severe corneal complications arise.
• Ears:
  • External ear anomalies (microtia, anotia, malrotation, cupping) in >95% of cases
  • Atresia or stenosis of the external auditory canal in ~50–60%
  • Middle ear abnormalities: malformed ossicles (esp. malleus/incus), absent tympanic cavity, hypoplastic mastoids
  • Conductive hearing loss affects >75% of patients; sensorineural or mixed losses occur in ~15–20% (usually with POLR1C/D mutations). Auditory brainstem response (ABR) and high-resolution temporal bone CT are recommended for diagnostic workup.

Other Associated Features

• Cleft palate/bifid uvula (~30%)
• Cardiac defects: Minor increased risk (~5–8% vs. 1% general population), mainly septal defects (ASD/VSD)
• Dental anomalies: Malformed, supernumerary, or delayed eruption
• Facial nerve variants: Branching anomalies in ~40% (e.g., duplicated facial nerve), increasing surgical risk during reconstructive procedures

Cognitive Development

Neurodevelopment is typically normal. IQ scores fall within the average range. Learning disabilities are no more common than in the general population—unless untreated hearing loss or comorbid syndromic features (e.g., CHARGE) coexist.

Diagnosis

Prenatal Diagnosis

• Ultrasound (18–22 weeks gestation): Detects severe micrognathia, abnormal facial profile, and polyhydramnios (secondary to feeding difficulty), but subtle findings are often missed.
• Genetic testing:
  • Targeted single-gene analysis (TCOF1) if familial variant known
  • Trio-based whole-exome sequencing (WES) for atypical or unsolved cases
  • Chorionic villus sampling (CVS, 10–13 weeks) or amniocentesis (15–20 weeks) for confirmation in high-risk pregnancies

Postnatal Diagnosis

• Clinical diagnosis based on major/minor criteria:
  • Major: Bilateral microtia/anotia, lower lid coloboma, malar hypoplasia, mandibular hypoplasia
  • Minor: Cleft palate, dental anomalies, facial nerve palsy
• Imaging:
  • High-resolution CT (HRCT) temporal bones (gold standard for osseous anatomy; recommended by AAP 2022 guidelines)
  • MRI: Assess soft tissue, facial nerve course, and intracranial structures if neurologic signs present

Differential Diagnosis & OMENS Classification

TCS overlaps phenotypically with other craniofacial dysostoses. The OMENS classification system (adapted from J Craniomaxillofac Surg, 2016; updated in Plast Reconstr Surg Glob Open, 2022) standardizes severity assessment:

Note: OMENS does not replace genetic diagnosis but complements surgical and prognostic planning.

Management: Multidisciplinary & Life-Cycle Approach

1. Neonatal Period:
   • Airway management: Lateral positioning, nasopharyngeal airway, or tracheostomy if severe obstruction (as in Pierre Robin sequence).
   • Feeding support: Specialized bottles (e.g., Habermann feeder), nasogastric or G-tube if oral intake insufficient.
   • Hearing screening: Newborn hearing screening (OAE/ABR) by 1 month; amplification by 3–6 months.
2. Auditory Rehabilitation:
   • Bone-conduction hearing aids (BAHA, softband) preferred in children <5 years.
   • Atresia repair (canalplasty ± ossiculoplasty) considered at age 5–7 if anatomy permits (success rate ~60–70% for functional gain).
3. Surgical Interventions:
   • Cleft palate repair: At 9–12 months
   • Mandibular distraction osteogenesis: For severe micrognathia with respiratory compromise (ideally <6 months)
   • Zygomatic/malar augmentation: Using autologous grafts or Medpor® implants, typically at age 5–7 or adolescence
   • Auricular reconstruction: staged cartilage grafts (Nagata or Brent techniques) starting at age 6–10
   • Facial nerve monitoring essential during all midface/auricular procedures
4. Speech & Language Therapy: Crucial for articulation outcomes, especially with cleft palate or hearing loss.
5. Psychosocial Support: High prevalence of bullying and anxiety. Early involvement of child psychologists, peer support groups (e.g., FACES: The National Craniofacial Association), and school advocacy is strongly recommended (AAP 2023 Clinical Report).
6. Genetic Counseling:
   • Recurrence risk: 50% if a parent is affected; <1% if de novo (due to germline mosaicism possible in ~5–10% of “apparent” de novo cases).
   • Preimplantation genetic diagnosis (PGD) available for known familial variants.

Prognosis & Long-Term Outcomes

• Life expectancy: Normal with appropriate perinatal care and airway management.
• Cognitive function: Typically normal; educational attainment matches peers when hearing and psychosocial needs are met.
• Quality of life: Significantly improved with modern reconstructive techniques and early intervention—most adults lead independent lives, pursue higher education, and work in diverse careers (including those requiring hearing, with accommodations).

Key Resources

• Treacher Collins Syndrome Foundation (https://www.treachercollins.org)
• NIH Genetic and Rare Diseases Information Center (GARD): https://rarediseases.info.nih.gov/diseases/7835/treacher-collins-syndrome
• American Academy of Pediatrics Clinical Report: Craniofacial Anomalies (2023)
• Leena Goel et al., BMJ Case Reports (2010); updated by recent consensus guidelines in Plastic and Reconstructive Surgery, 2024.